Osteogenic Enhancement Between Icariin and Bone Morphogenetic Protein 2: A Potential Osteogenic Compound for Bone Tissue Engineering

Overview

Journal Front Pharmacol

Date 2019 Mar 28

PMID 30914948

Citations 13

Authors

Xin Zhang

Xingnan Lin

Tie Liu

Liquan Deng

Yuanliang Huang

Yuelian Liu

Affiliations

Soon will be listed here.

Abstract

Icariin, a typical flavonol glycoside, is the main active component of Herba Epimedii, which was used to cure bone-related diseases in China for centuries. It has been reported that Icariin can be delivered locally by biomaterials and it has an osteogenic potential for bone tissue engineering. Biomimetic calcium phosphate (BioCaP) bone substitute is a novel drug delivery carrier system. Our study aimed to evaluate the osteogenic potential when Icariin was internally incorporated into the BioCaP granules. The BioCaP combined with Icariin and bone morphogenetic protein 2 (BMP-2) was investigated using an MC3T3-E1 cell line. We also investigated its efficacy to repair 8 mm diameter critical size bone defects in the skull of SD male rats. BioCaP was fabricated according to a well-established biomimetic mineralization process. , the effects of BioCaP alone or BioCaP with Icariin and/or BMP-2 on cell proliferation and osteogenic differentiation of MC3T3-E1 cells were systematically evaluated. , BioCaP alone or BioCaP with Icariin and/or BMP-2 were used to study the bone formation in a critical-sized bone defect created in a rat skull. Samples were retrieved for Micro-CT and histological analysis 12 weeks after surgery. The results indicated that BioCaP with or without the incorporation of Icariin had a positive effect on the osteogenic differentiation of MC3T3-E1. BioCaP with Icariin had better osteogenic efficiency, but had no influence on cell proliferation. BioCap + Icariin + BMP-2 showed better osteogenic potential compared with BioCaP with BMP-2 alone. The protein and mRNA expression of alkaline phosphatase and osteocalcin and mineralization were higher as well. , BioCaP incorporate internally with both Icariin and BMP-2 induced significantly more newly formed bone than the control group and BioCaP with either Icariin or BMP-2 did. Micro-CT analysis revealed that no significant differences were found between the bone mineral density induced by BioCaP with icariin and that induced by BioCaP with BMP-2. Therefore, co-administration of Icariin and BMP-2 was helpful for bone tissue engineering.

Citing Articles

Enhanced effects of slowly co-released TGF-β3 and BMP-2 from biomimetic calcium phosphate-coated silk fibroin scaffolds in the repair of osteochondral defects.

Chen J, Wang Y, Tang T, Li B, Kundu B, Kundu S J Nanobiotechnology. 2024; 22(1):453.

PMID: 39080653 PMC: 11290091. DOI: 10.1186/s12951-024-02712-0.

Promoting osteogenesis and bone regeneration employing icariin-loaded nanoplatforms.

Mohammadzadeh M, Zarei M, Abbasi H, Webster T, Beheshtizadeh N J Biol Eng. 2024; 18(1):29.

PMID: 38649969 PMC: 11036660. DOI: 10.1186/s13036-024-00425-4.

Nanotherapy for bone repair: milk-derived small extracellular vesicles delivery of icariin.

Yu X, Dong M, Wang L, Yang Q, Wang L, Han W Drug Deliv. 2023; 30(1):2169414.

PMID: 36714914 PMC: 9888478. DOI: 10.1080/10717544.2023.2169414.

Icariin Has a Synergistic Effect on the Osteoinductivity of Bone Morphogenetic Protein 2 at Ectopic Sites.

Zhang X, Lin X, Wang M, Deng L, Wei L, Liu Y Orthop Surg. 2023; 15(2):540-548.

PMID: 36628510 PMC: 9891965. DOI: 10.1111/os.13597.

Macrophage Polarization Related to Biomimetic Calcium Phosphate Coatings: A Preliminary Study.

Chen J, Zhou Y, Lin X, Li H Materials (Basel). 2023; 16(1).

PMID: 36614671 PMC: 9822186. DOI: 10.3390/ma16010332.

References

Kleeff J, Maruyama H, Ishiwata T, Sawhney H, Friess H, Buchler M . Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology. 1999; 116(5):1202-16. DOI: 10.1016/s0016-5085(99)70024-7. View

Uludag H, DAugusta D, Palmer R, Timony G, Wozney J . Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. J Biomed Mater Res. 1999; 46(2):193-202. DOI: 10.1002/(sici)1097-4636(199908)46:2<193::aid-jbm8>3.0.co;2-1. View

Bauer T, Muschler G . Bone graft materials. An overview of the basic science. Clin Orthop Relat Res. 2000; (371):10-27. View

Lewandrowski K, Gresser J, Wise D, Trantol D . Bioresorbable bone graft substitutes of different osteoconductivities: a histologic evaluation of osteointegration of poly(propylene glycol-co-fumaric acid)-based cement implants in rats. Biomaterials. 2000; 21(8):757-64. DOI: 10.1016/s0142-9612(99)00179-9. View

Borah B, Gross G, Dufresne T, Smith T, Cockman M, Chmielewski P . Three-dimensional microimaging (MRmicroI and microCT), finite element modeling, and rapid prototyping provide unique insights into bone architecture in osteoporosis. Anat Rec. 2001; 265(2):101-10. DOI: 10.1002/ar.1060. View

van den Bergh J, Ten Bruggenkate C, Krekeler G, Tuinzing D . Sinusfloor elevation and grafting with autogenous iliac crest bone. Clin Oral Implants Res. 2001; 9(6):429-35. DOI: 10.1034/j.1600-0501.1996.090608.x. View

Kurashina K, Kurita H, Wu Q, Ohtsuka A, Kobayashi H . Ectopic osteogenesis with biphasic ceramics of hydroxyapatite and tricalcium phosphate in rabbits. Biomaterials. 2002; 23(2):407-12. DOI: 10.1016/s0142-9612(01)00119-3. View

Shin H, Jo S, Mikos A . Biomimetic materials for tissue engineering. Biomaterials. 2003; 24(24):4353-64. DOI: 10.1016/s0142-9612(03)00339-9. View

Ray R, Holloway J . Bone implants; preliminary report of an experimental study. J Bone Joint Surg Am. 1957; 39-A(5):1119-28. View

10.

Pratap J, Galindo M, Zaidi S, Vradii D, Bhat B, Robinson J . Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res. 2003; 63(17):5357-62. View

11.

Zebboudj A, Shin V, Bostrom K . Matrix GLA protein and BMP-2 regulate osteoinduction in calcifying vascular cells. J Cell Biochem. 2003; 90(4):756-65. DOI: 10.1002/jcb.10669. View

12.

Liu Y, Hunziker E, Layrolle P, de Bruijn J, de Groot K . Bone morphogenetic protein 2 incorporated into biomimetic coatings retains its biological activity. Tissue Eng. 2004; 10(1-2):101-8. DOI: 10.1089/107632704322791745. View

13.

Aalami O, Nacamuli R, Lenton K, Cowan C, Fang T, Fong K . Applications of a mouse model of calvarial healing: differences in regenerative abilities of juveniles and adults. Plast Reconstr Surg. 2004; 114(3):713-20. DOI: 10.1097/01.prs.0000131016.12754.30. View

14.

Galindo M, Pratap J, Young D, Hovhannisyan H, Im H, Choi J . The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem. 2005; 280(21):20274-85. PMC: 2895256. DOI: 10.1074/jbc.M413665200. View

15.

Chen K, Ge B, Ma H, Liu X, Bai M, Wang Y . Icariin, a flavonoid from the herb Epimedium enhances the osteogenic differentiation of rat primary bone marrow stromal cells. Pharmazie. 2006; 60(12):939-42. View

16.

Phimphilai M, Zhao Z, Boules H, Roca H, Franceschi R . BMP signaling is required for RUNX2-dependent induction of the osteoblast phenotype. J Bone Miner Res. 2006; 21(4):637-46. PMC: 2435171. DOI: 10.1359/jbmr.060109. View

17.

Meijer G, de Bruijn J, Koole R, van Blitterswijk C . Cell-based bone tissue engineering. PLoS Med. 2007; 4(2):e9. PMC: 1800310. DOI: 10.1371/journal.pmed.0040009. View

18.

Zhang G, Qin L, Shi Y . Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial. J Bone Miner Res. 2007; 22(7):1072-9. DOI: 10.1359/jbmr.070405. View

19.

Habraken W, Wolke J, Jansen J . Ceramic composites as matrices and scaffolds for drug delivery in tissue engineering. Adv Drug Deliv Rev. 2007; 59(4-5):234-48. DOI: 10.1016/j.addr.2007.03.011. View

20.

Chen K, Ge B, Liu X, Ma P, Lu M, Bai M . Icariin inhibits the osteoclast formation induced by RANKL and macrophage-colony stimulating factor in mouse bone marrow culture. Pharmazie. 2007; 62(5):388-91. View